Strategic Markets PainTEQ operates in minimally invasive sacroiliac joint stabilization with recent scientific validation and a growing clinical footprint, presenting a sales opportunity to hospitals and ASC networks seeking evidence-based SI joint solutions and broader neuro-modulation alignment.

Clinical Evidence Recent ASPN conference findings and cortical-piercing posterior SI joint procedures create a compelling case to target biomedical researchers, clinical champions, and key opinion leaders to accelerate adoption and expand training partnerships.

Expansion Momentum Announcements around TRAQ technology, NANS 2026 involvement, and investments in clinical and commercial operations indicate a growth phase suitable for channel partnerships, distribution expansion, and aligned sales campaigns.

Strategic Partnerships Award recognition for venture capital and private equity deals signals mature market positioning; pursue collaboration with PE-backed distributors and hospital networks seeking scalable, data-backed SI joint solutions.

Financial Leverage Revenue in the mid single digits with a $35M funding runway suggests readiness for scaled pilots, bundled offerings, and outcome-based sales models to demonstrate value in cost-constrained healthcare settings.